ProCE Banner Series

CAR T-Cell Therapy in CLL, DLBCL, FL, and MCL: Current Evidence and Guidance to Support Optimal Integration into Care

Engage with expert faculty as they provide an in-depth review of CAR T-cell therapy in lymphoma, including case discussions, clinical considerations, and audience question and answer sessions.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced-degree nurses who care for patients with lymphomas who are potential CAR T-cell therapy candidates.

All Events

CAR T-Cell Therapy in CLL, DLBCL, FL, and MCL: Current Evidence and Guidance to Support Optimal Integration into Care

Past Events

September

10

2024

6:00 PM - 8:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Christopher J D'Andrea, PA-C

Hematology and Medical Oncology
Taussig Cancer Center
Cleveland Clinic
Cleveland, Ohio

ProCE Banner Faculty
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland, Ohio

ProCE Banner Faculty
Lisa Nodzon, PhD, APRN, AOCNP

Lead Advanced Practice Nurse
Department of Malignant Hematology
Moffit Cancer Center
Tampa, Florida

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with CAR-T. 

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced-degree nurses who care for patients with lymphomas who are potential CAR T-cell therapy candidates. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Differentiate the rationale for and mechanisms of CAR T-cell therapies vs other anticancer therapies in lymphomas, as well as current and anticipated CAR T-cell approvals.
  • Evaluate current and emerging efficacy and safety evidence for the use of CAR T-cell therapies in CLL/SLL, DLBCL, FL, and MCL and optimal sequencing of therapies.
  • Identify toxicities associated with CAR T-cell therapies and their recommended management strategies
  • Initiate discussions with patients on the requirements of CAR T-cell therapy, including eligibility criteria, early referral to specialized treatment centers, patient care coordination, and pre/post-treatment support

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours, including 2.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 2.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

Supported by an educational grant from Bristol Myers Squibb.